<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00689078</url>
  </required_header>
  <id_info>
    <org_study_id>08-003-05</org_study_id>
    <nct_id>NCT00689078</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge Model</brief_title>
  <official_title>A Single-Center, Randomized, Double-Masked Evaluation of the Efficacy of Prednisolone Acetate 1% Ophthalmic Suspension Compared to Prednisolone Acetate 0.12% Ophthalmic Suspension, Loteprednol Etabonate 0.2% Ophthalmic Suspension, and Placebo in a Modified Conjunctival Allergen Challenge (CAC) Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ORA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ORA, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether prednisolone acetate 1% ophthalmic
      suspension is effective in preventing signs and symptoms of allergic conjunctivitis in
      comparison with prednisolone acetate 0.12% ophthalmic suspension, loteprednol etabonate 0.2%
      ophthalmic suspension and placebo in a modified conjunctival allergen challenge (CAC) model.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular itching and conjunctival redness</measure>
    <time_frame>minutes post challenge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chemosis</measure>
    <time_frame>minutes post-challenge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lid swelling</measure>
    <time_frame>minutes post challenge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ciliary redness</measure>
    <time_frame>minutes post challenge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episcleral redness</measure>
    <time_frame>minutes post challenge</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisolone acetate 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisolone acetate 0.12%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Loteprednol Etabonate 0.2%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone Acetate 1%</intervention_name>
    <description>One drop OU</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Pred Forte</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone Acetate 0.12%</intervention_name>
    <description>One drop OU</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Pred Mild</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol Etabonate 0.2%</intervention_name>
    <description>One drop OU</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Alrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artificial tears</intervention_name>
    <description>One drop OU</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age &amp; either sex, any race

          -  Willing and able to follow all instructions

          -  Positive history of ocular allergies

          -  Reproducible positive ocular allergic reaction induced by conjunctival allergen
             challenge

        Exclusion Criteria:

          -  Have planned surgery during trial period

          -  Female currently pregnant, planning a pregnancy or lactating

          -  Use of disallowed medications

          -  Have ocular infections, or ocular conditions that could affect study parameters

          -  Have moderate to severe dry eye

          -  Have used an investigational drug or device within 30 days of start of study

          -  Female that is currently pregnant, planning a pregnancy or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail L Torkildsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Medical Society, Alpha Omega Honor Society, American board of Ophthalmology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ophthalmic Research Associates</name>
      <address>
        <city>North Andover</city>
        <state>Massachusetts</state>
        <zip>01845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2008</study_first_submitted>
  <study_first_submitted_qc>May 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2008</study_first_posted>
  <last_update_submitted>May 13, 2009</last_update_submitted>
  <last_update_submitted_qc>May 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>Paul Gomes</name_title>
    <organization>Ophthalmic Research Associates</organization>
  </responsible_party>
  <keyword>Allergic conjunctivitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
    <mesh_term>Loteprednol Etabonate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 26, 2010</submitted>
    <returned>September 17, 2010</returned>
    <submitted>September 20, 2010</submitted>
    <returned>October 5, 2010</returned>
    <submitted>October 26, 2010</submitted>
    <returned>November 24, 2010</returned>
    <submitted>December 16, 2010</submitted>
    <returned>January 18, 2011</returned>
    <submitted>June 20, 2011</submitted>
    <returned>July 15, 2011</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

